Comparison of Outcomes after Transcatheter vs Surgical Aortic Valve Replacement among Patients at Intermediate Operative Risk with a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial
Reardon, M.J., Heijmen, R.H., Van Mieghem, N.M., Williams, M.R., Yakubov, S.J., Watson, D., Kleiman, N.S., Conte, J., Chawla, A., Hockmuth, D., Petrossian, G., Robinson, N., Kappetein, A.P., Li, S., & Popma, J.J. (2019, June 19).
Comparison of outcomes after transcatheter versus surgical aortic valve replacement among patients at intermediate operative risk with a history of coronary artery bypass graft surgery: A post hoc analysis of the SURTAVI randomized clinical trial. JAMA Cardiol. doi:10.1001/jamacardio.2019.1856
By Jonathan Scheiner, Research Assistant
Expanding on the value of TAVR over traditional aortic valve surgery, the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial enrolled over 1600 patients, including patients from St. Francis Hospital. Dr. George Petrossian and Dr. Newell Robinson significantly contributed to this important study. Both TAVR and aortic valve surgery patients were assessed and compared. TAVR patients were found to have significantly shorter hospital stays and were significantly less likely to be sent to additional additional care facilities than traditional surgery patients. Furthermore, TAVR patients showed significantly greater ability to exercise and reported significantly higher quality of life after one month and after one year. Although this study indicated both TAVR and aortic valve surgery as overall safe for patients, the significantly faster patient discharges and improved outcomes further highlight TAVR as the safe, effective method for treating aortic stenosis in a wide variety of patients.